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Transfemoral Is Better*Giuseppe Bruschi, MD, Nuccia Morici, MDS evere aortic stenosis (AS) is the most frequentform of valvular heart disease in Western coun-tries, and symptomatic AS has become an
increasing health problem for their growing elderly
populations. The lethality of symptomatic AS has
been recognized for decades; it has a high and rapid
rate of mortality in untreated patients that ap-
proaches 50% over the ﬁrst 2 years (1). Aortic valve
replacement (AVR) is still the current gold standard
of treatment for these patients; it has been proven
to prolong and improve quality of life in good opera-
tive candidates and can be performed with acceptable
mortality in elderly patients. However, surgery is
often prohibitive in patients with multiple or severe
comorbidities and high operative risk (2).
The PARTNER (Placement of AoRTic TraNs-
cathetERValve Trial Edwards SAPIEN Transcatheter
Heart Valve) trials were a fundamental break-
through in this ﬁeld. The PARTNER-B trial investi-
gated the safety and efﬁcacy of transcatheter aortic
valve replacement (TAVR) in patients deemed un-
suitable for surgical AVR by randomizing inoperable
patients with severe symptomatic AS to medi-
cal therapy or TAVR (3). In the PARTNER-A trial,
patients who had severe, symptomatic AS and
were considered to be at high risk for surgery
were randomized to TAVR or standard AVR (4).
TAVR was far superior to medical therapy in the
PARTNER-B trial and was not inferior to surgery in
the PARTNER-A trial.SEE PAGE 158
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compare when and how deaths occurred in both the
PARTNER-A and PARTNER-B trials. A total of 3,105
patients were evaluated for potential inclusion in
the PARTNER trials; 699 patients were considered
to be at high risk for open surgery (PARTNER-A
trial), and 358 patients were considered inoperable
(PARTNER-B trial). Before randomization, it was
determined whether each patient was suitable for a
transfemoral (TF) approach (n ¼ 244) or a transapical
(TA) approach (n ¼ 104), depending on vascular
access. In addition, 351 patients were randomized to
AVR. The baseline patient characteristics were similar
among the subsets in the PARTNER-A trial and
between the treatment arms in the PARTNER-B trial.
Median follow-up was 2 years and 1.3 years for pa-
tients in the PARTNER-A and PARTNER-B trials,
respectively. Deaths were categorized as cardiovas-
cular, noncardiovascular, or uncategorizable.
In the PARTNER-B trial, the rates of death were
56.9% in the TAVR group and 75.4% in the standard
therapy group; the corresponding rates of cardiac
death were 39.2% and 49.6%, respectively. There was
an early peak of instantaneous risk of death among
patients randomized to standard therapy that was
prolonged beyond 6 months, possibly related to
balloon aortic valvuloplasty (BAV). In fact, 114 pa-
tients assigned to standard therapy underwent BAV
during the 30 days after randomization and 36
patients underwent BAV more than 30 days after
randomization. Patients who underwent BAV, com-
pared with those who did not, appeared to have more
favorable outcomes for at least the ﬁrst 6 months af-
ter randomization to standard therapy (6). Regard-
less, the patients in the standard therapy group
remained at considerably higher risk compared with
the general population throughout the 2.5 years of
follow-up, and the instantaneous risk of cardiovas-
cular death remained elevated well above the risk
after randomization of patients to TAVR. Patients
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170treated with TAVR had markedly improved overall
survival compared with standard therapy. Survival
diverged between the 2 trial arms within 30 to
60 days, and the gap widened thereafter. The net
lifetime added by TF-TAVR over standard therapy
was on average a half-year within 2.5 years of
randomization. When considering the magnitude of
the reduction in mortality seen after TAVR, absolute
mortality remained a sobering 56.9% after a median
follow-up of 1.3 years. Therefore, it would be
worthwhile to identify the patients excluded from
surgery who would derive little or no long-term
beneﬁt from TAVR due to coexisting conditions or
comorbidities that would limit their life expectancy.
In a subgroup analysis of mortality outcomes ac-
cording to surgical risk (on the basis of Society of
Thoracic Surgeons [STS] score) by Makkar et al. (6)
on 2-year data, the mortality beneﬁt with TAVR
decreased with increasing STS score. Therefore,
TAVR should be considered the standard of care for
selected inoperable patients with an expected sur-
vival commensurate with or better than that of the
general population. On that basis, the 2014 AHA/ACC
Guideline for the Management of Patients With
Valvular Heart Disease (7) recommends TAVR for
high-risk patients with severe symptomatic AS who
are unable to undergo surgical AVR because of a
prohibitive surgical risk to improve survival and
reduce symptoms (Class I, Level of Evidence: B).
In the PARTNER-A trial, the rates of death were
lower with no signiﬁcant difference between the
surgery group (39.6%) and the transcatheter group
(39.0%); however, there was a difference in overall
mortality between the TF-TAVR group (36.9%) and
the TA-TAVR group (44.2%). The corresponding
rates of cardiac death were 36.7% in the TF-TAVR
group, 21.7% in the TA-TAVR group, and 33.1% in
the AVR group. The TA-TAVR group had 37% unca-
tegorized deaths. The instantaneous unadjusted risk
of death peaked early after randomization in both
the AVR and TA-TAVR groups, falling within 3 to
6 months to a low level commensurate with that of
matched U.S. population estimates; conversely, the
instantaneous risk of death of TF-TAVR was only
modestly elevated from the date of randomization.
This pattern of early risk resulted in separation of
TF-TAVR survival curves from those of AVR and
TA-TAVR. The conditional probability of dying
was higher with the surgical approach and lower
with transcatheter procedures, mostly if performed
with the TF approach. The treatment effect was
greater in the ﬁrst 30 days. After the ﬁrst month,
only a slight difference was seen, with conﬁdence
intervals quite comparable in width. Interestingly,patients undergoing surgical procedures and pa-
tients undergoing TA-TAVR were at higher risk for
noncardiovascular events. Twenty patients died be-
tween randomization and the procedure, including
3 patients assigned to TAVR (1 patient assigned to
TA-TAVR) and 17 patients assigned to AVR, but only
7 of these patients died within the ﬁrst 30 days
after randomization. Considering that patient allo-
cation was performed using a random process and
baseline features were matched to prevent selection
bias, it should be inferred that the increased non-
cardiovascular mortality was related to the surgical
and TA approach; although the early risk of car-
diovascular death was higher with TF-TAVR, it
was related to periprocedural factors and probably
due to the difference between access sites. The TA
procedure is performed via an anterolateral mini-
thoracotomy in the ﬁfth or sixth intercostal space
to obtain straight access to the left ventricular apex.
Notably, 15% of all deaths in patients undergoing
TA-TAVR were related to respiratory failure, which
was signiﬁcantly higher than with TF-TAVR (3.3%)
and AVR (6.4%). In addition, the use of the TA
approach involves the puncture and the introduc-
tion of a large catheter through the ventricular apex
($24-F, with external diameter $7.9 mm). This
has been associated with a greater increase (up to
4 times higher) in cardiac biomarkers of myocardial
injury with the presence of signiﬁcant myocardial
necrosis at the level of the left ventricular apex
in such patients as well as less improvement in
left ventricular ejection fraction during follow-up
(8). As a result, 0.13 year of lifetime was gained
within 2.5 years by TF-TAVR over AVR, 0.22 year
by TF-TAVR over TA-TAVR, and 0.087 year by AVR
over TA-TAVR. The PARTNER-B trial supports the
use of TAVR as an alternative to surgery in selected
high-risk patients with AS, and the 2014 AHA/ACC
Guideline for the Management of Patients With
Valvular Heart Disease (7) recommends the use of
TAVR as a reasonable alternative to surgical AVR
but restricted to patients with a high-risk surgi-
cal proﬁle given the limited known long-term
outcomes and valve durability (Class IIa, Level of
Evidence: B).
In patients at high risk for surgery, TA-TAVR and
AVR were associated with elevated periprocedural
risk more than TF-TAVR, particularly for noncardio-
vascular death. Therefore, when feasible, TF-TAVR
should be considered a less invasive approach and
the standard of care for the implantation of balloon-
expandable transcatheter aortic bioprosthesis. In
the near future, with improvements in valve and
sheath technology, more and more patients with a
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171lower risk proﬁle will most likely be treated with
TF-TAVR. However, it is still important to evaluate
whether other proximal, less invasive, alternative
approaches to TF-TAVR, such as axillary and direct
aortic approaches, will lead to better results than
TA-TAVR.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Giuseppe Bruschi, “A. De Gasperis” Cardiology &
Cardiac Surgery Department, Niguarda Ca’ Granda
Hospital, Piazza dell’Ospedale Maggiore 3, 20162
Milan, Italy. E-mail: giuseppe.bruschi@fastwebnet.it.RE F E RENCE S1. Bonow RO, Carabello BA, Chatterjee K, et al.
2008 focused update incorporated into the ACC/
AHA 2006 guidelines for the management of
patients with valvular heart disease: a report of
the American College of Cardiology/American
Heart Association Task Force on Practice Guide-
lines. J Am Coll Cardiol 2008;52:e1–142.
2. Charlson E, Legedza AT, Hamel MB. Decision-
making and outcomes in severe symptomatic aortic
stenosis. J Heart Valve Dis 2006;15:312–21.
3. Leon MB, Smith CR, Mack M, et al. Trans-
catheter aortic-valve implantation for aortic ste-
nosis in patients who cannot undergo surgery.
N Engl J Med 2010;363:1597–607.4. Smith CR, Leon MB, Mack MJ, et al. Trans-
catheter versus surgical aortic-valve replacement in
high-risk patients. N Engl JMed 2011;364:2187–98.
5. Svensson LG, Blackstone EH, Rajeswaran J,
et al. Comprehensive analysis of mortality
among patients undergoing TAVR: results of the
PARTNER trial. J Am Coll Cardiol 2014;64:158–68.
6. Makkar RR, Fontana GP, Jilaihawi H, et al.
Transcatheter aortic-valve replacement for inop-
erable severe aortic stenosis. N Engl J Med 2012;
366:1696–704.
7. Nishimura RA, Otto CM, Bonow RO, et al. 2014
AHA/ACCguideline for themanagement of patientswith valvular heart disease: executive summary: a
report of the American College of Cardiology/
American Heart Association Task Force on Practice
Guidelines. J Am Coll Cardiol 2014;63:2438–88.
8. Rodes-Cabau J, Gutierrez M, Bagur R, et al.
Incidence, predictive factors, and prognostic value
of myocardial injury following uncomplicated
transcatheter aortic valve implantation. J Am Coll
Cardiol 2011;57:1988–99.KEY WORDS aortic stenosis, causes of death,
TAVR
